Home Heroes De Novo Discovery Gene Scan CDx Pathway ♻️ Repurposing 🚦 Gates Models Quantum 🧪 Wet Lab Schedules 🎛️ Control 🧬 CIFOG 📈 Milestones 🧬 BioBrain 🧠 NPEAD Architecture 🔬 RODE 🧠 Cortex-R Workspace 🧠 V2 🧠 V3 📦 Knowledge 💰 Revenue 🧪 Tests 📊 Costs 📚 Datasets

🧬 FGF17 — Discovery Report

📄 Autonomous discovery by Cortex · 2026-05-22

Gene	FGF17
Full Name	Fibroblast Growth Factor 17
Target Protein	FGF17_protein
Cancer Type	Prostate / Pancreatic
Grade	A+
Priority	HIGH
Stage	lead_candidate
Novelty	FIRST-IN-CLASS (0 ChEMBL)

🧬 BioBrain ⚖️ Decisions

Scientific Hypothesis

"FGF17 drives paracrine proliferation and angiogenesis from tumor stroma. Blocking FGF17 starves tumor of stromal support signals."

Mechanism of Action

Pathway: FGF17 → FGFR → RAS/MAPK + PI3K → proliferation + angiogenesis

Clinical Angle: Anti-stromal therapy: block FGF17 to cut tumor supply lines

Docking Results

Metric	Value
Best Vina Score	-8.7 kcal/mol
Best Molecule (SMILES)	`O=C(Cc1ccc2ncccc2c1)Nc1ccc(C(=O)O)cc1`
Molecular Weight	306.3 Da
QED / DCSAL	0.707
Molecules Tested	10
Docking Method	smina (real GPU, g4dn.xlarge)
Receptor Source	AlphaFold v4

5-Dimension Scoring

🎯 Binding: 0.87 🔬 Pathway: 0.86 💡 Innovation: 0.95 💊 Therapy: 0.87 ⭐ Novelty: 1.0 🧬 BioBrain ⚖️ Decisions

Total Score: —

Governance

PQM Status	ISSUED
QCM Trust	1.0
Ledger Logged	✅ SHA-256 hash chain
Evidence ID	RO-FGF17
Authority	marcus_60 (sole override)

Conclusion

FGF17 is a FIRST-IN-CLASS (0 ChEMBL) target with A+ grade binding affinity (-8.7 kcal/mol). The mechanistic hypothesis (FGF17 → FGFR → RAS/MAPK + PI3K → proliferation + angiogenesis) provides a clear therapeutic rationale for Prostate / Pancreatic. Anti-stromal therapy: block FGF17 to cut tumor supply lines. Recommended for wet lab validation.

MindNetQ Inc. — Governed Intelligence for Precision Medicine
Report generated by Cortex autonomous discovery pipeline. All decisions ledger-hashed.